MedTrace Logo

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

NCT02934022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-10-14

No results posted yet for this study

Summary

Many patients on Highly Active Antiretroviral Therapy (HAART) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their CD4 counts to levels greater than 500. Adding maraviroc to the treatment regimen of these patients may result in an increase in their CD4 counts. As the patient would be continuing their prior regimen, they will likely continue with full control of viral replication.

Conditions

  • HIV Infection

Interventions

DRUG

Maraviroc

150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Southern California Institute for Research and Education

    lead OTHER

Principal Investigators

  • Stephen M. Berman, MD, PhD · VA Long Beach Healthcare System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02934022 on ClinicalTrials.gov